Drug data last refreshed 16h ago · AI intelligence enriched 4w ago
TESLAC is an injectable small-molecule product approved by Bristol Myers Squibb in 1969 with an unknown mechanism of action and indication profile. As a legacy NDA product, it represents a mature therapeutic asset with established clinical use but limited modern clinical development activity.
Approaching loss of exclusivity with moderate competitive pressure (30/100), suggesting downsizing commercial operations and transition planning for end-of-life brand management.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on TESLAC in a LOE-approaching environment means focusing on maximizing existing market presence, defending against generic competition, and planning organizational transition. Career development is limited; this role is best suited for professionals interested in lifecycle management, cost-containment strategy, or transition planning rather than launch or growth opportunities.
Worked on TESLAC at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.